WO2023141504A2 - Dcas9-intégrase pour édition de génome ciblé - Google Patents

Dcas9-intégrase pour édition de génome ciblé Download PDF

Info

Publication number
WO2023141504A2
WO2023141504A2 PCT/US2023/060898 US2023060898W WO2023141504A2 WO 2023141504 A2 WO2023141504 A2 WO 2023141504A2 US 2023060898 W US2023060898 W US 2023060898W WO 2023141504 A2 WO2023141504 A2 WO 2023141504A2
Authority
WO
WIPO (PCT)
Prior art keywords
sequence
plasmid
encodes
antibiotic resistance
replication
Prior art date
Application number
PCT/US2023/060898
Other languages
English (en)
Other versions
WO2023141504A3 (fr
Inventor
Eli Tijerina LYONS
Charlane Joy CARDOS
Elena Natsumi KAYAYAN
Original Assignee
Genomeminer, Inc. (Formally Tupac Bio, Inc.)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genomeminer, Inc. (Formally Tupac Bio, Inc.) filed Critical Genomeminer, Inc. (Formally Tupac Bio, Inc.)
Publication of WO2023141504A2 publication Critical patent/WO2023141504A2/fr
Publication of WO2023141504A3 publication Critical patent/WO2023141504A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]

Definitions

  • the invention concerns an improved, targeted genome editing platform using the dCas9-Integrase fusion protein.
  • Genome editing and gene therapy are of great interest for the prevention and treatment of diseases such as single gene disorder (e.g., sickle cell disease), cancer, heart disease, mental illness and HIV. See e.g., Park S.H., Lee C.M., et.al. Therapeutic Crisps/Cas9 Genome Editing for Treating Sickle Cell Disease. Blood 2016 128:4703, and complex diseases (e.g., fatal genetic diseases), England S.B., Nicholson L.V., Johnson M.A., Very Mild Muscular Dystrophy Associated with the Deletion of 46% of Dystrophin, Nature 1990; 343(6254).
  • diseases such as single gene disorder (e.g., sickle cell disease), cancer, heart disease, mental illness and HIV. See e.g., Park S.H., Lee C.M., et.al. Therapeutic Crisps/Cas9 Genome Editing for Treating Sickle Cell Disease. Blood 2016 128:4703, and complex diseases (e.g., fatal genetic
  • Genome editing has the ability to precisely and efficiently introduce a variety of genetic alterations into microbes, plant cells and mammalian cells via the insertion of a DNA sequence, the deletion of a DNA sequence or region, or the removal and replacement of one DNA sequence with another sequence. See e.g., Katare D.P. and Aeri V., Progress in Gene Therapy: A Review, I.J.T.P.R. 2010;l:33; Gardlik R., Palffy R., Hodosy J., Lukacs J., Turna J., Celec P., Vectors and Delivery Systems in Gene Therapy, Med Sci Monit. 2005; 11:110-21; and Wu Z., Yang H., Colosi P., Effect of Genome Size on AAV Vector Packaging, 2010 Mol. Ther. 18:80-86.
  • Genome editing facilitated by a CRISPR-Cas system complexes a protein and gRNA to guide and cleave specific DNA regions and incorporate foreign DNA into a precise location of a host genome.
  • CRISPR /Cas9 system for genome editing: progress, implications and challenges, Human Molecular Genetics, Volume 23, Issue Rl, 15 September 2014, Pages R40-R46, Liang Z, Zhang K, Chen K, Gao C. Targeted mutagenesis in Zea mays using TALENs and the CRISPR/Cas system. J Genet Genomics.
  • fusion proteins e.g., dCas9-Transposase, Target- AID
  • Strecker J Ladha Am Gardner Z, Burgk S, Makarova K, Koonin E, Zhang F., RNA-guided DNA insertion with CRISPR-associated transposases. 2019 Jul 5;365(6448):48-53. doi: 10.1126/science. aax9181.
  • Some of these previously developed gene-editing techniques are susceptible to off-target errors, can have low efficiency, can be immunogenic or toxic to target cells, are often expensive, time-consuming to use, difficult to engineer, and may have limited targetable sites.
  • these previously developed CRISPR-based techniques have been attributed to causing unwanted off target effects, which can alter the functions of the gene, which in turn can lead to genomic instability, that can potentially disrupt the normal function of genes, hindering CRISPR’s prospective application in clinical trials. See e.g., Goff S.P., Genetics of Retroviral Integration, Ann. Rev. Genet.
  • Microbes are good targets for CRISPR-Cas system because they produce a variety of compounds ranging from fuels to chemicals and drugs.
  • bioreactors are used to scale up the compound synthesis.
  • the culture conditions for commercially available bioreactors are often different from the laboratory flasks setting and it has been observed that some microbe strains do not grow equally in both environments. See e.g., Humphrey A., Shake Flask to Fermentor: What Have We Learned?, Biotechnol. Progress. 1998; 14: 3-7.
  • Plasmids are often used to express genes in a host microbial cell. These circular DNA pieces are the main vectors of horizontal gene transfer among bacteria for long term bacterial adaptation. Halary S., Leigh J.W., Cheaib B., Lopez P., Bapteste E., Network Analyses Structure Genetic Diversity in Independent Genetic Worlds, Proc. Natl Acad. Sci. USA 107, 127-132 (10.1073/pnas.0908978107 (2009)).
  • ZFN Zinc-finger nucleases
  • RNAi RNA interference
  • TALEN transcription activator-like effector nucleases
  • CRISPR-Cas9 tools has been used to engineer model industrial organisms such as Saccharomyces cerevisiae and Escherichia coli to facilitate high product formation without fatal consequences to the host organism, therefore the integration of target gene into the genome is preferable.
  • Pingfang Tian Jia Wang, Xiaolin Shen, Justin Forrest Rey, Qipeng Yuan, Yajun Yan, Fundamental CRISPR-Cas9 tools and current applications in microbial systems, Synthetic and Systems Biotechnology, Volume 2, Issue 3, 2017, Pages 219-225, ISSN 2405-805X, doi: https://doi.org/10.1101/423012; Zerbini. F., Zanella, I., Fraccascia, D.
  • an improved gene editing tool is needed to reduce off-target effects, improve efficiency and increase the range of targetable sites in the host genome.
  • Disclosed herein is a novel and precise genome editing platform that can deliver a genetic element of interest to a precise location on a host genome with the one or more of the following benefits: low off target effects compared to similar gene-editing technologies available, ability to target any region in any genome with high precision; and low toxicity/susceptibility of causing an immune response.
  • dCas9-Integrase provides a customizable, genome-editing platform which improves upon previous genome-editing methods. Fusion proteins are formed by linking two proteins with a short linker sequence.
  • dCas9-Int consists of the catalytically dead Cas9 protein linked to the HIV-integrase enzyme.
  • the linker sequence may be SGSETPGTSESATPES (SEQ ID NO: 20), or some other sequence.
  • the dCas9-Int may also include a start codon and/or a stop codon.
  • the dCas9-Int fusion protein is then encoded into a backbone vector, resulting in a plasmid that expresses the catalytically dead mutant Cas9 (dCas9) linked to HIV Integrase by a short linker.
  • the plasmid can contain a crRNA sequence that is complementary to the target sequence lacZ of the host genome HB101, however the sgRNA is customizable so that any crRNA can be cloned into the backbone dCas9-Int protein to target any DNA sequence in the host’s genome.
  • dCas9-Int may also be encoded in a plasmid.
  • a plasmid may include a sequence that encodes a mutant Cas9 endonuclease from a Streptococcus pyogenes with a D10A mutation in the RuvC catalytic domain and a H480A mutation in the HNH catalytic domain and a sequence that encodes the HIV Integrase protein.
  • the plasmid may also include a tracrRNA sequence and/or a crRNA sequence.
  • the crRNA sequence in the plasmid may be customized to include a hybridization of a sequence to be modified in a host genome.
  • the plasmid may also include a sequence that encodes antibiotic resistance, such as a sequence that encodes Ampicillin, Carbenicillin, Chloramphenicol, Hygromycin B, Kanamycin, Spectinomycin and/or Tetracycline resistance.
  • the plasmid can further include a sequence that encodes an origin of replication, such as a pBR322 origin of replication and a Cas9 native promoter.
  • a plasmid containing a sequence that encodes the dCas9-Int fusion protein can be constructed with a sgRNA sequence and/or a sequence that encodes for antibiotic resistance.
  • the sgRNA sequence may comprises a crRNA sequence and a tracrRNA sequence, where the crRNA sequence may be customizable to hybridize with a sequence on the host genome.
  • the sequence that encodes for antibiotic resistance may be specific to Ampicillin, Carbenicillin, Chloramphenicol, Hygromycin B, Kanamycin, Spectinomycin and/or Tetracycline.
  • the dCas9-Int and sgRNA plasmid may include a sequence that encodes an origin of replication, such as a pBR322 origin of replication.
  • a pTransO4 plasmid may also be constructed with a sequence that includes U5*U3 long terminal repeats from an HIV-1 virus, a sequence that has multiple cloning sites, and a sequence that encodes antibiotic resistance genes.
  • the pTransO4 plasmid may also include an origin of replication, such as the pl5A origin of replication, and/or a sequence that encodes antibiotic resistance genes.
  • the antibiotic resistance can be resistance to one or more of the following antibiotics: Ampicillin, Carbenicillin, Chloramphenicol, Hygromycin B, Kanamycin, Spectinomycin and/or Tetracycline.
  • a cell can express a dCas9-Int plasmid and a pTransO4 plasmid.
  • the dCas9-Int plasmid may or may not include an origin of replication such as the pBR322 origin of replication, and the pTransO4 plasmid may or may not include a different origin of replication, such as the pl5A origin of replication.
  • the dCas9-Int plasmid might include a tracrRNA sequence and/or a crRNA sequence.
  • the crRNA sequence may be customizable to include a hybridization of a sequence to be modified in a host genome.
  • the dCas9-Int plasmid may include a sequence that encodes antibiotic resistance, such as a sequence that encodes resistance to one or more of the following antibiotics: Ampicillin, Carbenicillin, Chloramphenicol, Hygromycin B, Kanamycin, Spectinomycin or Tetracycline.
  • a dCas9-Int plasmid can include a customizable crRNA sequence that is capable of hybridizing to the target sequence in the host genome.
  • the dCas9-Int plasmid can be introduced into a host cell, where the customizable crRNA sequence hybridizes to the target sequence in the host genome, causing the target sequence in the host genome to be modified.
  • the host cell can be a eukaryotic cell, a plant cell, an algae cell, a non-human cell, or a mammalian cell.
  • the dCas9-Int plasmid may include a sequence that encodes for antibiotic resistance, including one or more of the following antibiotics: Ampicillin, Carbenicillin, Chloramphenicol, Hygromycin B, Kanamycin, Spectinomycin or Tetracycline. Further the dCas9-Int plasmid may include an origin of replication, and the customizable crRNA sequence may be linked to a tracrRNA sequence. dCas9-Int can also be combined with sgRNA to form a complex. The complex can be used with a plasmid which contains a genetic element of interest to modify a host genome. The genetic element of interest may include a sequence that can hybridize with a target sequence in the host genome.
  • the plasmid may include a sequence that encodes for antibiotic resistance, such as one or more of the following antibiotics: Ampicillin, Carbenicillin, Chloramphenicol, Hygromycin B, Kanamycin, Spectinomycin or Tetracycline.
  • the plasmid may also include an origin of replication.
  • the sgRNA protein may be comprised of crRNA and tracrRNA.
  • Fig. 1(a) illustrates a dCas9-Integrase fusion protein.
  • Fig. 1(b) (SEQ ID NO: 1) illustrates a sequence for the dCas9-Integrase fusion protein.
  • Fig. 1(c) illustrates the dCas9-Integrase targeting mechanism.
  • Fig. 2(a) illustrates an sgRNA sequence, a dCas9-Integrase protein and a linear genetic element of interest.
  • Fig. 2(b) illustrates a complex formed from the dCas9-Integrase, sgRNA, a linear genetic element of interest and a target sequence on the host genome.
  • Fig. 2(c) illustrates a target modification to the host genome caused by the complex shown in Fig. 2(b).
  • Fig. 2(d) illustrates the components of a complex to be formed, specifically, dCas9-Integrase, sgRNA, and a circular genetic element of interest.
  • Fig. 2(e) illustrates a complex formed from dCas9-Integrase, sgRNA, a circular genetic element of interest and a target on the host genome.
  • Fig. 2(f) illustrates a resulting target modification to the host genome, where the target sequence on the host genome is replaced with a sequence from the circular genetic element of interest.
  • Fig. 3(a) illustrates a sequence of the pFusion02.1 plasmid.
  • Fig. 3(b) illustrates an embodiment of the pFusion02.2 plasmid.
  • Fig. 3(c) (SEQ ID NO: 3) illustrates a sequence for the pFusion02.2 plasmid.
  • Fig. 4(a) illustrates an embodiment of the pFusion02.3 plasmid.
  • Fig. 4(b) (SEQ ID NO: 4) illustrates a sequence for the pFusion02.3 plasmid.
  • Fig. 5(a) illustrates an embodiment of the pFusion02.4 plasmid.
  • Fig. 5(b) illustrates crRNA fused to tracrRNA to form an sgRNA molecule for the pFusion02.4 plasmid.
  • Fig. 5(c) (SEQ ID NO: 5) illustrates a sequence for the pFusion02.4 plasmid.
  • Fig. 6 illustrates a sequence for the pFusion02.5 plasmid.
  • Fig. 7(a) illustrates an embodiment of the pFusion03(mammalian) plasmid.
  • Fig. 7(b) illustrates an alternative embodiment of the pFusion03(mammalian) plasmid.
  • Fig. 7(c) illustrates crRNA fused to tracrRNA to form an sgRNA molecule for the pFusion03 (mammalian) plasmid.
  • Fig. 7(d) illustrates a sequence for the pFusion03(mammalian) plasmid.
  • Fig. 8 (SEQ ID NO: 8) illustrates a sequence for the pSP72B vector.
  • Fig. 9(a) illustrates an embodiment of the pTransO4 plasmid.
  • Fig. 9(b) illustrates an embodiment of the pTransO4 plasmid with the origin of replication removed.
  • Fig. 9(c) (SEQ ID NO: 9) illustrates a sequence for the pTransO4 plasmid.
  • Fig. 10(a) illustrates a custom-designed guiding crRNA sequence.
  • Fig. 10(b) illustrates a tracrRNA sequence.
  • Fig. 11 illustrates an embodiment where the pFusion02.2 plasmid and the pTransO4 plasmid are both expressed in the same cell.
  • Fig. 12 illustrates a pBR322 origin of replication sequence.
  • dCas9 A catalytically dead mutant of the Cas9 endonuclease from the Streptococcus pyogenes Type II CRISPR/Cas system. It is an RNA-guided, DNA-binding protein that lacks endonuclease activity due to the D10A mutation in the RuvC catalytic domain and the H840A mutation in the HNH catalytic domain. dCas9 is used in CRISPR systems along with gRNAs to target specific host genome locations.
  • Integrase An enzyme produced by a retrovirus (e.g., HIV) that integrates its DNA into a host genome's DNA.
  • linker A short sequence of DNA that connects the dCas9 protein with Integrase.
  • single-guide RNA (sgRNA) An RNA sequence that contains both a custom-designed crRNA sequence fused to a scaffold tracrRNA sequence.
  • fusion protein system A system that consists of dCas9 and the Integrase protein joined together by a linker.
  • plasmid A circular, double-stranded DNA molecule that is physically separated from chromosomal DNA and replicates itself independently from chromosomal DNA.
  • transformation The process of horizontal gene transfer wherein a foreign DNA strand is taken up by bacterial cells.
  • transfection The process of intaking foreign DNA or purified nucleic acid into eukaryotic cells.
  • off-target error An unintended genetic modification in the host genome resulting from the application of gene editing techniques.
  • Chemical DNA synthesis The process of synthesizing DNA sequences using chemical methods which are usually carried out when the DNA sequence does not occur naturally or contains base modifications.
  • DNA Sequence A sequence consisting of DNA nucleotides.
  • Hybridizing combining two complementary single-stranded DNA or RNA molecules and allowing them to form a single double- stranded molecule through base pairing.
  • Protein Sequence A sequence consisting of amino acids.
  • host genome A genome carried by a host organism, whether a prokaryote or eukaryote, to be edited. gene editing or editing: inserting, removing, or removing then replacing one or more nucleotides in a host’s genome.
  • the structure of the dCas-Int protein includes a start codon, followed by a catalytically dead mutant of the Cas9 endonuclease from the Streptococcus pyogenes Type II CRISPR/Cas system.
  • dCas9 is an RNA-guided, DNA-binding protein that lacks endonuclease activity due to the D10A mutation in the RuvC catalytic domain and H840A mutation in the HNH catalytic domain.
  • the dCas9 protein is followed by a short linker that links the dCas9 to the HIV Integrase protein. The most efficient linker was used in the fusion protein described in Guillinger 2014.
  • the HIV Integrase gene is inserted after the linker, such that the HIV Integrase sequence is from GenBank: L21188.1. Finally, the dCas9-Int protein is terminated with stop codon, as shown in Fig. 1(a).
  • the HIV Integrase protein allows efficient integration of DNA into a target DNA sequence.
  • the sequence for dCas9-Int protein is shown Fig. 1(b) and consists of 1367 amino acids (SEQ ID NO: 1).
  • dCas9-Int provides a customizable genome-editing platform which improves upon previous genome-editing methods by linking two proteins, resulting in the creation of a novel fusion protein, dCas9-Int.
  • dCas9-Int can be encoded into backbone vector, resulting in a plasmid that expresses the fusion protein of catalytically dead-Cas9 (dCas9) linked to HIV integrase by a short linker.
  • the dCas9-Integrase fusion protein can be assembled as follows.
  • the pSP72A vector is digested at Hpal and Aatll restriction sites to clone the insert dCas9-Integrase sequence.
  • For the insert fusion protein start from the sequences [‘upstream of tracrRNA' until ‘after Direct repeat (DR)'] from the Bhatt et. al 2019 (infra) plasmid sequence pRC2311 (with pl promoter from Michael Tellier, Ronald Chalmers, A series of constitutive expression vectors to accurately measure the rate of DNA transposition and correct for auto-inhibition BioRxiv 2019, doi: https://doi.org/10.1101/423012.
  • Fig. 1(c) illustrates an embodiment that demonstrates the dCas9-Int targeting and editing mechanisms in operation.
  • a cell is transfected with a plasmid that expresses the dCas9-Int protein and an appropriately designed sgRNA sequence.
  • the sgRNA is comprised of a crRNA sequence, GTCACGACGTTGTAAAACGA (SEQ ID NO: 12), linked to scaffold tracrRNA sequence.
  • the crRNA sequence is complimentary to the target sequence CAGTGCTGCAACATTTTGCT (SEQ ID NO: 13) in the host genome.
  • the crRNA recognizes the target DNA sequence in the host’s genome, just upstream of the PAM sequence (in this case GCC) and binds to that portion of the host’s genome.
  • dCas9-Int then cuts both strands of DNA to match the crRNA sequence, allowing a replacement DNA sequence to be inserted into a precise location in the host’s genome.
  • dCas9-Int can be combined with other components to form a gene editing mechanism. For example, as shown in Fig. 2(a), dCas9-Int can be combined with sgRNA and linear genetic element of interest to form a complex.
  • dCas9-Int is mentioned in W02016/161207 in conjunction with a linear genetic element of interest, the inventors herein have determined experimentally that a linear genetic element of interest is not suitable if dCas9-Int is to be used for gene editing.
  • a linear genetic element of interest is easily digested by nucleases inside the cell, whereas circular genetic elements of interest minimize the degradation and are able to replicate. Accordingly, a circular genetic element of interest is preferrable, as shown in Figs. 2(d) and 2(e) (discussed further below).
  • dCas9-Int, sgRNA and a circular genetic element of interest can be combined to form a complex that can modify a target sequence in the host’s genome, as shown in Fig. 2(b).
  • the target sequence in the host genome is replaced with the genetic element of interest.
  • Fig. 2(d) shows the components of a gene editing mechanism, including a circular genetic element of interest (i.e., a plasmid), a fusion protein such as dCas9-Int, and sgRNA.
  • a circular genetic element of interest i.e., a plasmid
  • a fusion protein such as dCas9-Int
  • sgRNA a fusion protein
  • Fig. 2(e) shows a complex formation consisting of dCas9-Int, sgRNA, and a circular genetic element of interest annealed to a target sequence in the host genome.
  • Fig. 2(f) shows the genetic element of interest that has replaced the target sequence in the host genome.
  • dCas9-Int can be incorporated into a plasmid, such as the pFusion02.2 plasmid.
  • dCas9-Int can be incorporated into a variety of other plasmids as well.
  • One way to construct these plasmids is through DNA synthesis.
  • the following elements are included in the pFusion02.1 and pFusion02.2 plasmids: dCas9-Int, which is the fusion of a catalytically dead Cas9 protein linked to the Integrase protein by a short linker, and an sgRNA sequence that contains customizable crRNA and tracrRNA, where the crRNA binds to the target sequence in the host’s genome.
  • Some optional elements include: (1) ampR: a sequence that codes for the ampicillin resistant gene for antibiotic selection (genes resistant to other antibiotics can be used interchangeably); (2) a stuffer sequence: a short DNA sequence (e.g., GAGACGAGTCTCGGAAGCTCAAACGTCTC)(SEQ ID NO: 14), that can be digested by the BsmBI restriction enzyme and cloned with any unique crRNA sequences; and (3) ORI: a low-copy Origin of Replication, such as pBR322, to initiate the plasmid replication.
  • the tracrRNA is controlled by a downstream promotor while the dCas9-Int is controlled by an upstream, Cas9 native promoter.
  • the sequence for the pFusion02.1 plasmid (SEQ ID NO: 2) is shown in Figure 3(a) and the sequence for the pFusion02.2 plasmid (SEQ ID NO: 3) is shown in Figure 3(c).
  • one embodiment of the pFusion02.1 plasmid consists of 8163 base pairs, including a sequence that codes for Ampicillin resistance (a sequence that codes for a different type of antibiotic resistance can also be used); a sequence that codes for a tracrRNA; and a sequence that codes for the dCas9-Int protein.
  • Fig. 1 consists of 8163 base pairs, including a sequence that codes for Ampicillin resistance (a sequence that codes for a different type of antibiotic resistance can also be used); a sequence that codes for a tracrRNA; and a sequence that codes for the dCas9-Int protein.
  • one embodiment of the pFusion02.2 plasmid consists of 8204 base pairs, including a sequence that codes for the pBR322 origin of replication; a sequence that codes for Ampicillin resistance (a sequence that codes for a different type of antibiotic resistance can also be used); a sequence that codes for a tracrRNA and a sequence that codes for the dCas9-Int protein.
  • a crRNA sequence short oligonucleotides (oligos) a and b are synthesized separately and annealed.
  • the pSP72A plasmid is digested with the BsmBI restriction enzyme and cloned with the annealed oligos.
  • the oligo sequences are as follows:
  • Oligo a AAACGGTTTTCCCAGTCACGACGTTGTAAAACGAG (SEQ ID NO:
  • Oligo b AAAACTCGTTTTACAACGTCGTGACTGGGAAAACC (SEQ ID NO:
  • Fig. 4(a) shows another embodiment, the pFusion02.3 plasmid, which is a dCas9-Int along with a pFusion02.2 plasmid that had its origin of replication (“ORI”) removed using digestion enzymes and was self-ligated to re-circulize the plasmid. Removal of the ORI prevents the plasmid from replicating after transformation. Low expression and transient expression of the fusion protein avoids problems that can result from too many copies of the fusion protein plasmids.
  • the sequence for the pFusion02.3 plasmid (SEQ ID NO: 4) is illustrated in Fig. 4(b).
  • Fig. 5(a) is an embodiment of the pFusion02.4 plasmid.
  • the pFusion02.4 plasmid comprises a sequence that expresses the dCas9-Int fusion protein, a sequence that expresses sgRNA, a sequence that expresses Ampicillin resistance gene and an ORI.
  • the sequences that express other types of antibiotic resistances can be substituted for the sequence that expresses Ampicillin resistance.
  • dCas9-Int and sgRNA sequences are controlled by upstream promotors, while the sequence that expresses Ampicillin resistance is controlled by a downstream promoter.
  • Fig. 5(b) illustrates sgRNA for the pFusion02.4 plasmid.
  • Fig. 5(c) illustrates an embodiment of the pFusion02.4 plasmid sequence (SEQ ID NO: 5).
  • the pFusion02.4 plasmid consists of 8204 base pairs, including a sequence that codes for the pBR322 origin of replication, a sequence that codes for Ampicillin (or other types of antibiotic) resistance, a sequence that codes for a tracrRNA sequence and a sequence that codes for the dCas-Int protein.
  • Fig. 6 illustrates an embodiment of the pFusion02.5 plasmid sequence.
  • one embodiment (SEQ ID NO: 6) of the pFusion02.5 plasmid consists of 7576 base pairs, including a sequence that codes for Ampicillin (or some other type of antibiotic) resistance, a sequence that codes for a tracrRNA sequence and a sequence that codes for the dCas-Int protein.
  • Fig. 7(a) illustrates an embodiment of the pFusion03 plasmid for mammalian cell expression.
  • the pFusion03 plasmid shown in Fig. 7(a) includes a sequence that codes for the dCas9-Int fusion protein; an ORI; a sequence that codes for Ampicillin resistance (or other types of antibiotic resistance can be substituted for Ampicillin resistance); a sequence that codes for sgRNA that targets the chr4:58110375-58110396 region in the host genome, (or other sequences that codes for sgRNA that targets any region in the host genome); and three promoters that regulate the sgRNA, dCas9-Int and ampR elements.
  • the sgRNA and dCas-Int elements are designed to create a complex that allows a custom sequence of the host’s genome to be modified.
  • Fig. 7(b) illustrates an alternative embodiment of the pFusion03 (mammalian) plasmid.
  • the pFusion03 plasmid includes a sequence that expresses the dCas9-Int fusion protein, a sequence that expresses a customizable sgRNA that targets a portion of the host genome, and a sequence that expresses Ampicillin resistance (sequences that express other types of antibiotic resistance can also be used).
  • the sequences that code for dCas9-Int and sgRNA are each controlled by a separate upstream promoter.
  • the sequence that codes for the Ampicillin resistance is controlled by a downstream promoter.
  • FIG. 7(c) illustrates crRNA fused to tracrRNA to form an sgRNA molecule for the pFusion03 (mammalian) plasmid.
  • Fig. 7(d) illustrates a sequence for the pFusion03 (mammalian) plasmid (SEQ ID NO: 7).
  • a related embodiment sequence is pFusion03 mammalian-base plasmid sequence (SEQ ID NO: 11).
  • Fig. 8 illustrates a sequence (SEQ ID NO: 8) for the pSP72B vector, which is used to construct a mammalian plasmid.
  • the pSP72B vector is made by modifying a pSP72 plasmid from Promega, digested at Aatll restriction site to insert the multi-cloning Sequence A, to obtain the pSP72A vector.
  • MCS Multiple Cloning Site
  • Figs. 9(a) and 9(b) illustrate an embodiment a pTransO4 plasmid, which can be constructed as follows with the necessary elements to allow efficient ligation into the target genome.
  • the pTrans-04 is a small circular, low-copy or no-copy plasmid containing the
  • a low copy ORI such as the pl5A origin of replication (pl5A ORI).
  • MCS Multi-Cloning Site
  • an antibiotic resistant gene such as a gene that is resistant to kanamycin (genes that are resistant to other antibiotics can be used interchangeably).
  • Fig. 9(b) shows the pTransO4 (no ORI) plasmid, specifically, the origin of replication was removed using digestion enzymes and was self-ligated to re-circulize the plasmid. Note that the antibiotic resistance gene is optional. Of course, for the pTransO4 (no ORI) plasmid, replication does not occur after transformation.
  • Fig. 9(c) illustrates a sequence for the pTransO4 plasmid (SEQ ID NO: 9).
  • Figs. 10(a) and 10(b) illustrates sgRNA, composed of a crRNA sequence linked to tracrRNA.
  • Fig. 10(a) shows a guiding sequence composed of crRNA.
  • the crRNA includes a custom-designed targeting sequence that is complimentary to the target DNA sequence in the host’s genome.
  • the crRNA sequence is 20 plus base pairs, and because it is complimentary to the DNA of interest in the host’s genome, it directs the dCas9 nuclease activity to that region on the host genome.
  • Fig. 10(b) illustrates tracrRNA, fused to the crRNA. The crRNA hybridizes with the tracrRNA to form sgRNA.
  • Fig. 11 illustrates an embodiment where a bacterial cell expresses both the pFusion02.2 plasmid and the pTRANS-04 plasmid. Both plasmids will be able to co-exist inside a single cell by designing each plasmid to have different ORI (e.g., one plasmid can have a pBR322 ORI, while the other plasmid can have a pl5A ORI), or by synthesizing one of the plasmids so that it does not contain an ORI. Specifically, the 2 plasmids can co-exist in a single cell if the respective origins of replication are different or only 1 plasmid has an origin of replication.
  • ORI e.g., one plasmid can have a pBR322 ORI, while the other plasmid can have a pl5A ORI
  • the pFusion02.2 plasmid can express the dCas9-Int fusion protein, while pTRANS-04 plasmid can express multiple cloning sites in order to clone different sgRNAs for specific target sequences.
  • Fig. 12 is an embodiment (SEQ ID NO: 10) of a pBR322 origin of replication sequence.
  • the pBR322 origin of replication sequence consists of 648 base pairs from the pBR322 plasmid, created in 1977 in the laboratory of Herbert Boyer at the University of California.
  • the 648 base pairs of pBR322 shown in Fig. 12 are well-suited as an origin of replication for the pFusion02.2 and pFusion02.3 plasmids, disclosed herein, although there are other sequences that can be used for the origin of replication for these plasmids.
  • the fusion proteins described herein can also be produced independently and used in combination with synthetic sgRNA. Also, by way of example, the fusion proteins described herein can be used without transformation or transfection of DNA plasmids coding for such a fusion protein and related elements such as sgRNA. Further, the plasmids disclosed herein can be synthesized or assembled using molecular cloning techniques, or copied through transformation and amplification in e.coli or other microbes, as these techniques are well known.
  • Various embodiments can be obtained by means of chemical DNA synthesis, or could be made using molecular biology cloning and DNA construction techniques to obtain a plasmid expressing the dCas9-Int fusion protein.
  • a plasmid that expresses a dCas9-Int protein could then be applied in combination with various molecular biology techniques such as transformation and transfection to edit any target DNA sequence in many types of organisms.
  • Certain aspects of the gene editing system described herein can be purchased and modified. For example, crRNA can be synthesized and inserted into the backbone plasmid in order for genome edits to occur at a custom target of interest. With this, genome editing can occur at any target location in the host genome.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Une protéine de fusion pour l'édition de gènes, qui combine la protéine Cas9 mutante catalytiquement inactive avec l'enzyme intégrase du VIH, à l'aide d'une séquence de liaison courte a été développée. La protéine de fusion résultante est appelée dCas9-intégrase. La dCas9-intégrase peut être codée dans un seul plasmide pour contenir une séquence qui exprime la protéine dCas9-intégrase et la séquence d'ARNcr qui est complémentaire d'une séquence cible dans un génome hôte, créant une plateforme d'édition du génome destinée à modifier n'importe quelle séquence d'ADN dans le génome hôte.
PCT/US2023/060898 2022-01-19 2023-01-19 Dcas9-intégrase pour édition de génome ciblé WO2023141504A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263300652P 2022-01-19 2022-01-19
US63/300,652 2022-01-19

Publications (2)

Publication Number Publication Date
WO2023141504A2 true WO2023141504A2 (fr) 2023-07-27
WO2023141504A3 WO2023141504A3 (fr) 2023-09-14

Family

ID=87349130

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/060898 WO2023141504A2 (fr) 2022-01-19 2023-01-19 Dcas9-intégrase pour édition de génome ciblé

Country Status (1)

Country Link
WO (1) WO2023141504A2 (fr)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3365356B1 (fr) * 2015-10-23 2023-06-28 President and Fellows of Harvard College Éditeurs de nucleobases et leurs utilisations
JP2022540318A (ja) * 2019-06-11 2022-09-15 ウニベルシタット ポンペウ ファブラ 標的遺伝子編集構築物およびそれを使用する方法

Also Published As

Publication number Publication date
WO2023141504A3 (fr) 2023-09-14

Similar Documents

Publication Publication Date Title
Kim et al. Efficient CRISPR editing with a hypercompact Cas12f1 and engineered guide RNAs delivered by adeno-associated virus
Wang et al. Multiplex gene editing in rice using the CRISPR-Cpf1 system
Zhang et al. Progress in genome editing technology and its application in plants
KR101785847B1 (ko) 선형 이중가닥 ＤＮＡ를 활용한 ＣＲＩＳＰＲ／Ｃａｓ９ 시스템을 이용한 표적 유전체 교정
Xing et al. A CRISPR/Cas9 toolkit for multiplex genome editing in plants
Ao et al. A multiplex genome editing method for Escherichia coli based on CRISPR-Cas12a
JP2023546597A (ja) 部位特異的標的化エレメントによるプログラム可能な付加（ｐａｓｔｅ）を使用した部位特異的遺伝子操作のためのシステム、方法及び組成物
CN107922949A (zh) 用于通过同源重组的基于crispr/cas的基因组编辑的化合物和方法
EP2141238B1 (fr) Plasmides de vecteur de clonage d'ADN et leurs procédés d'utilisation
Wong et al. Efficient and seamless DNA recombineering using a thymidylate synthase A selection system in Escherichia coli
CN106715694A (zh) 核酸酶介导的dna组装
EP3204513A2 (fr) Oligonucléotides crispr et édition de gènes
JP2004121248A (ja) 複数遺伝子組換えベクターコンストラクトの作成方法とその応用
JP2012024099A (ja) Ｄｎａクローニングベクタープラスミドのダイナミックなベクター構築のための方法
CN102703424B (zh) 一种重组工程介导的大肠杆菌基因组点突变的方法
Sung et al. Combining orthogonal CRISPR and CRISPRi systems for genome engineering and metabolic pathway modulation in Escherichia coli
WO2014102688A1 (fr) Nouvelle matrice de conception pour l'amélioration du ciblage génique dirigé par homologie
CN104152414B (zh) 对细胞基因组的预定位点进行基因改造的方法
Shola et al. New additions to the CRISPR toolbox: CRISPR-CLONInG and CRISPR-CLIP for donor construction in genome editing
Randazzo et al. gEL DNA: A cloning-and polymerase chain reaction–free method for CRISPR-based multiplexed genome editing
WO2023141504A2 (fr) Dcas9-intégrase pour édition de génome ciblé
Mingarro et al. Improvements in the genetic editing technologies: CRISPR-Cas and beyond
KR20180128864A (ko) 매칭된 5' 뉴클레오타이드를 포함하는 가이드 rna를 포함하는 유전자 교정용 조성물 및 이를 이용한 유전자 교정 방법
Vu et al. Prime editing: Mechanism insight and recent applications in plants
Wen et al. A CRISPR/dCas9-assisted system to clone toxic genes in Escherichia coli

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23743907

Country of ref document: EP

Kind code of ref document: A2